139886-22-9

Basic information

• Product Name: (E)-N-ethoxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine hydrochloride (1:1)
• CAS NO: 139886-22-9
• Molecular Formula: C₉H₁₇ClN₂O
• Molecular Weight: 204.6971
• Mol File: 139886-22-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 240.3°C at 760 mmHg
• Flash Point: 99.1°C
• Vapor Pressure: 0.0383mmHg at 25°C
• CAS DataBase Reference: (E)-N-ethoxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine hydrochloride (1:1)(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-N-ethoxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine hydrochloride (1:1)(139886-22-9)
• EPA Substance Registry System: (E)-N-ethoxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine hydrochloride (1:1)(139886-22-9)

Safety Data

• Hazardous Substances Data: 139886-22-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(E)-N-ethoxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine hydrochloride (1:1) could be used as an active pharmaceutical ingredient for the development of new drugs, targeting various medical conditions due to its unique chemical structure.
Used in Research and Development:
In the field of scientific research, this compound might serve as a key intermediate or a model compound in the synthesis of more complex molecules or for studying its chemical properties and reactivity.
Used in Chemical Synthesis:
It may also be utilized as a reagent or a building block in the synthesis of other organic compounds, particularly those with potential applications in material science, pharmaceuticals, or agrochemicals.

Upstream product

• 3332-29-4 O-ethylhydroxylamine hydrochloride 
• 114485-45-9 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxaldehyde hydrochloride 

Relevant articles and documents

1-Alkyl-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-alkyl-oximes: A new class of potent orally active muscarinic agonists related to arecoline

On the basis of the knowledge acquired for basic studies of several known arecoline derivatives about the structural requirements for potent agonistic activity and oral efficacy, a series of 1-alkyl-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-alkyl-oximes was synthesized and biologically evaluated in a battery of in vitro and in vivo assays. The most interesting molecules to emerge from the primary screening, 1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-methyloxime hydrochloride (11, RU 35963), 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxyaldehyde-O-methyloxime hydrochloride (12, RU 35926), and 1,2,5,6-tetrahydropyridine-3-carboxyaldehyde-O-propargyloxime hydrochloride (30, RU 47029) and 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-propargyloxime hydrochloride (33, RU 35986), were evaluated more extensively, and their cholinomimetic profile was compared with that of the parent molecule, arecoline. The pharmacological results after oral administration to mice and rats revealed that their efficacy is 2-3 orders of magnitude higher than that of arecoline, and, in addition, they show a longer duration of action. The 4 aldoximes showed anti-amnesic properties in many respects superior to those of arecoline. Their anti-amnesic doses were 2 orders of magnitude lower than those inducing obvious cholinergic symptoms, and 3-5 orders of magnitude lower than the lethal doses. These new compounds can be regarded as potential candidates for clinical studies in AD (Alzheimer's disease) patients.